REVIEW | *Inflammation, Immunity, Fibrosis, and Infection*

Helminths in the gastrointestinal tract as modulators of immunity and pathology

Fumi Varyani,1,2 John O. Fleming,3 and Rick M. Maizels1
1Wellcome Centre for Molecular Parasitology, Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom; 2Edinburgh Clinical Academic Track, Western General Hospital, University of Edinburgh, Edinburgh, United Kingdom; and 3Department of Neurology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin

Submitted 18 January 2017; accepted in final form 12 March 2017

Varyani F, Fleming JO, Maizels RM. Helminths in the gastrointestinal tract as modulators of immunity and pathology, *Am J Physiol Gastrointest Liver Physiol* 312: G537–G549, 2017. First published March 16, 2017; doi:10.1152/ajpgi.00024.2017.—Helminth parasites are highly prevalent in many low- and middle-income countries, in which inflammatory bowel disease and other immunopathologies are less frequent than in the developed world. Many of the most common helminths establish themselves in the gastrointestinal tract and can exert counter-inflammatory influences on the host immune system. For these reasons, interest has arisen as to how parasites may ameliorate intestinal inflammation and whether these organisms, or products they release, could offer future therapies for immune disorders. In this review, we discuss interactions between helminth parasites and the mucosal immune system, as well as the progress being made toward identifying mechanisms and molecular mediators through which it may be possible to attenuate pathology in the intestinal tract.

Helminth Infections are highly prevalent in most tropical and developing countries, yet notably, these areas also suffer relatively low levels of “diseases of modernity” associated with hyperactive immune responsiveness (105, 181). While economic development has reduced or eliminated helminth infections, there has been an inexorable rise in the incidence of immunological disorders such as allergy, autoimmunity, and inflammatory bowel disease. One possible explanation is that helminths (and the immunomodulatory molecules they produce) directly modulate the host immune system to attenuate development of antiparasite immunity, in a manner that may also dampen bystander immune pathologies (104, 116).

Helminths are multicellular worm parasites that have evolved to occupy a vast range of niches, including the gastrointestinal tract of vertebrate hosts (Table 1). In general, they establish long-lived, chronic infections characterized by widespread downmodulation of both the innate and adaptive arms of host immunity. Hence, the presence of intestinal helminths may block the same inflammatory pathways that are responsible for allergies and autoimmunity, raising the potential for novel therapies based on the molecules and/or the pathways that parasites have evolved to suppress host immune reactions (51, 69, 113).

Even today, helminth infections affect around one quarter of people in the world (74, 140) and in historic times would have been near universal in the human population, so that these parasites have been long-term companions acting to shape the immune system. Indeed, helminth parasitism of the vertebrate gastrointestinal tract has been noted in fossils dating to the early Cretaceous period, ~125 million years ago (MYA) (138); additionally, the ubiquitous presence of geohelminths, such as the genus *Trichuris*, in many animal species suggests that parasite coevolution paralleled the mammalian adaptive radiation, starting 65 MYA. In fact, gastrointestinal helminth parasitism is likely present in virtually every mammal residing in a “natural” habitat.

Obviously, some parasitic species, especially those of relatively recent introduction to humans, are a major public health scourge and cause significant morbidity and mortality worldwide (75). On the other hand, the long coevolutionary history of helminths and their hosts has resulted in many parasites being relatively well tolerated and even contributing through their subtle dampening of inflammation to an optimal immunological balance (1). Thus, in modern times, the absence of helminths may lead to the immune system “overshooting” and mounting deleterious responses to harmless environmental and self-antigens.

Importantly, in many instances, a host’s environment includes external and endogenous microbes, which must be tolerated or even accepted as beneficial. In immunological terms, there is a continuum from commensal microbes through to the “macrobiotics,” such as helminths (55). Across this entire
ulcerative colitis, Crohn’s disease, and multiple sclerosis, to immune conditions, asthma, type 1 diabetes, rheumatoid arthritis, first by encompassing the full range of allergic and autoimmune disorders (114, 137). These and many other authors have evolved into various forms of the “hygiene hypothesis” (11, 101, 185). These and many other authors have evolved into various forms of the “hygiene hypothesis” (11, 101, 185). Second, early forms of the hygiene hypothesis proposed that early life microbial infections protected against allergy by promoting Th1-type responses at the expense of the proallergic Th2 arm of immunity, which mediates allergy. However, most nonallergic inflammatory conditions are themselves Th1 (and/or Th17) mediated, arguing against a simple Th1/17 vs. Th2 seesaw determining inflammatory status. With the recognition that eukaryotic parasites are also very effective at dampening immunological reactivity of their host through regulatory T-cell (Treg) expansion (101, 183), the hygiene hypothesis expanded to evoke immunosuppressive regulatory cells as a key pathway by which infectious agents could impact on the control of allergies and autoimmune disorders (50, 102).

Further significant reformulations of the hygiene hypothesis include the “Old Friends hypothesis” (146), which emphasizes protection provided by evolutionary ancient commensal and environmental microbiota, as well as the “Microflora hypothesis” (129, 148), which focuses on the role of gut bacteria in shaping systemic immune responses and extends the role of dietary metabolites (171), and finally, the “Biodiversity hypothesis” (67), which underscores potential health effects in a biosphere impacted by loss of biodiversity and by climate change. Bringing all this together, Filyk and Osborne (49) have introduced the term “multibiome” to comprehensively describe the bacteria, viruses, fungi, and multicellular organisms, which together colonize the gastrointestinal system and influence immune homeostasis in health and disease. Thus, while helminth parasites share the host environment with multiple other forms of life, it is notable that numerous epidemiological,
animal model, and clinical investigations have identified a prominent role of helminths in putative protection from allergy and autoimmunity, often linked to the regulatory arm of the immune system (59, 68, 105, 161). It is interesting to note that Tregs are also implicated in many studies of the microbiota’s influence on host immunity (57). In particular, *Bacteroides fragilis* expresses polysaccharide A, which induces Tregs to protect mice from colitis (149). Similarly, species of *Bifidobacterium* (131), *Clostridium* (8, 9), and *Lactobacillus* (83) have all been shown to induce Tregs in the gut, which are important in creating a stable anti-inflammatory environment (145). Failure or an imbalance in this process may result in pathology, most notably, inflammatory bowel disease (IBD) (13).

The association between parasite infection and reduced prevalence of immune disorders was first noted by Greenwood (62) in 1968 with respect to rheumatoid arthritis in African populations with high endemic helminth exposure. Subsequently, the first clear evidence of the role of parasitic infections in modulating allergy came from studies on Gabonese school children in an area endemic for schistosomiasis; infected children had lower reactivity (measured by skin prick testing) than uninfected contemporaries (174); moreover, when infected children were given antihelminthic therapy, they showed an increase in mite skin test positivity (175). Similar data linking helminth infections with attenuated allergy have been reported in South American populations by independent investigators (5, 28).

Helminths may also modulate many other inflammatory and autoimmune conditions in humans. A series of reports on multiple sclerosis patients in Argentina linked remission of disease with acquisition of gastrointestinal helminth infections (29) and found disease relapses following clearance of parasites in a subset of these patients (30). In a population-based study in Zimbabwe, schistosome-infected subjects bore lower levels of circulating autoimmune antinuclear antibody, which increased significantly following antischistosome therapy (125). Finally, with respect to inflammatory bowel diseases, there are both case reports (17) and small-scale trials indicating that helminth infections can confer a protective effect on patients (44, 181).

The original hygiene hypothesis focused on early life imprinting of the immune system by environmental exposure to microbes; however, helminths may similarly exert lifelong effects. Parasite-specific tolerance was induced in children of mothers exposed to the filarial nematode parasite *Wuchereria bancrofti* in pregnancy (163). Early life exposure to helminths also modulates responses to allergens, as shown by a study in which antihelminthic treatment of pregnant mothers resulted in a higher incidence of atopic eczema in infants than in those born to untreated infected mothers (124). Furthermore, childhood exposure to helminths was found to be protective against both Crohn’s disease and ulcerative colitis (24).

This fascinating interaction between environmental imprinting during infection and the known genetic predisposition of humans to inflammatory diseases (155) raises an interesting question of mechanism, which may be answered by arena field of epigenetics. Epigenetics refers to stable and inheritable alterations in gene expression without altering the DNA nucleotide sequence but through chemical modification of DNA bases (e.g., methylation) and DNA-associated histone proteins (by methylation and acetylation) (7). Prime examples of plasticity following environmental challenge are epigenetic alterations in innate immune cells, such as macrophages (151), as well as activated effector and T lymphocytes (182). Indeed, reports are already emerging on epigenetic control of the response to helminth parasites (21, 27, 72), as well as in a range of inflammatory diseases (7, 98, 132), suggesting that epigenetic research will provide a strong theoretical and empirical basis for understanding the modulatory effects of helminths in the gastrointestinal tract during autoimmunity and allergy.

The increase in immunological reactivity following antihelminthic clearance demonstrates, however, that the immune system is not always immutably imprinted by parasite exposure, but responsive to its current infection status. In fact, helminth infection in later life can very clearly downmodulate immune hyperactivity (104, 116, 181), leading as discussed below to trials using live parasites to treat inflammatory conditions such as IBD (168) and celiac disease (51, 112).

**Helminths and the Immune System**

Helminth parasites encompass a myriad of different life histories with particular dynamics and properties, which drive a wide diversity of immune responses (Table 1). Together with multiple environmental variables (coinfections, comorbidities, diet, and climate) and polymorphisms in host immune response genes, it is not surprising that different helminth infections may either exacerbate or ameliorate allergy and autoimmunity (111, 153, 161), and consideration of immune modulation by helminths must take these other factors into account.

In humans and livestock, intestinal helminths include the nematode roundworms and the cestode tapeworms. Each species possesses a particular migratory cycle and tropism and generally localizes to a specialized anatomical niche. For example, schistosomes, hookworms, and *Strongyloides* larvae penetrate unbroken skin and travel to the lung before migrating either to the mesenteric vasculature or the lumen of the gut. Other parasites, such as immature stages of tapeworms and the nematode *Trichinella*, leave the gut to encyst in muscle for transmission to a new carnivorous host. Such helminths can cause severe inflammation as in the case of schistosome trematodes, releasing eggs that either transit through the intestinal wall or lodge in the liver causing fibrosis (16, 48). However, apart from the blood-feeding hookworms, many of the parasites that establish in the intestinal lumen are not directly pathogenic to their surrounding tissue.

The immune response to helminths is generally dominated by the type 2/Th2 pathway that serves to directly trap, kill, or expel parasites, alongside an expanded Treg compartment that modulates and dampens inflammation (63, 100). This creates an environment in which helminths cannot thrive while also promoting repair of the physical damage caused by the worms (1, 54) and is in contrast to the classical inflammatory type 1 response targeted at bacterial and viral microorganisms.

The type 2 response is principally effected through the IL-4Rx and STAT6 pathways (1, 173), driven by either or both IL-4 and IL-13. In helminth infections, type 2 immunity is initiated at the site of invasion by epithelial cells, which release
the alarmins IL-25 and IL-33, inducing innate lymphoid cells (ILCs) to produce IL-13 and other cytokines. In the absence of either IL-25 or IL-33, resistance to helminth infections is severely impaired (127), as is the case in IL-4Rα or STAT6 deficiency (173).

The IL-4Rα-dependent adaptive immune response includes antigen-specific Th2 lymphocytes that produce cytokines IL-4, IL-5, IL-9, and IL-13 (176), and type 2 phenotype (M2) alternatively activated macrophages (90). Type 2 macrophages are centrally involved in the antihelminth response and repair mechanisms through molecules such as arginase-1, TIMP1 and -2 (inhibitors of metalloproteases), and IGF-1, which promotes fibroblasts and myofibroblast matrix formation (2, 90).

Tregs police the immune system to prevent untoward inflammatory reactions against self-antigens and innocuous environmental substances, while also terminating responses to pathogens when no longer required (152). They characteristically express the transcription factor Forkhead box P3 (Foxp3) and suppress both effector Th1 and Th2 cells through both direct cell surface interactions and by the secretion of TGF-β and IL-10. A defect in the Foxp3 gene results in fatal autoimmunity (34, 154, 159, 170). Reflecting the dependence of helminths on the regulatory compartment, it has been found that some helminths are able to induce the development of Tregs to modulate the immune response (61, 186).

It is important to recognize also that the immune response to helminth infection may evolve dramatically over time, following developmental changes in parasite migration or maturation, and/or time-dependent switches in immune activation or regulation. A classic example is in schistosomiasis, in which an initial Th1 response is superseded by a dominant Th2 mode once parasite egg release has commenced (135). Similarly, Nutman (130) and Santiago and Nutman (153) have mapped the evolution of a typical immune response to helminths, from the initiation of infection at mucosal surfaces, when a broad and robust inflammation, primarily mediated by effector Th1, Th2, and Th17 CD4+ cells, attempts to abort the infection; if unsuccessful, a period of weeks or months following, during subacute or latent infection is characterized by a more limited or focused Th2 reaction, primarily mediated by Th2 CD4+ cells, IL-4, IL-5, and eosinophils, which together minimize parasitic load. If a chronic infection is established over the succeeding months or years, the host response becomes essentially immunomodulatory and is primarily mediated by regulatory cells (1, 44, 50, 161) and anti-inflammatory cytokines (e.g., IL-10 and TGF-β) to assure that low levels of helminths are tolerated and immune homeostasis prevails. While this vignette is, of course, oversimplified, it well illustrates the alternative modes of antihelminth immune responsiveness and is important in considering whether immune modulation is differentially evoked during different phases of infection (45, 97).

**Immune Mechanisms in the Gastrointestinal Tract**

The intestine is the crucial barrier surface that must both obtain nutrition and protect the host. In this milieu, the immune system is constantly exposed to pathogens and foreign antigens, and its cells must discriminate pathogenic from harmless stimuli to mount protective responses, while maintaining homeostasis by tolerating food antigens, nonpathogenic bacteria, and helminths (79, 136). In addition, the immune system must compensate for the effects of the pathogen, reducing both the damage caused by the pathogen itself and the collateral immunemediated damage necessary to clear the invading organism (22).

The epithelial cells of the intestine, which are the first responders to gut infection, consist of the enterocytes, goblet cells, neuroendocrine cells, Paneth cells, and tuft cells. Together, the intestinal epithelial cells perform an essential barrier role, including intercellular tight junctions, which prevent pathogens from breaching the GI tract (6). The epithelial cells express pattern recognition receptors, such as Toll-like receptors and nucleotide-binding oligomerization domain-like receptors to sense pathogenic bacterial products such as LPS. Epithelial cells also respond to physical invasion and trauma by releasing alarmin cytokines that stimulate innate lymphoid and dendritic cells to initiate an immune response.

Distributed along the small intestinal epithelium, particularly in the more distal ileum, are lymphoid aggregates known as Peyer’s patches (82). Each patch is surrounded by follicle-associated epithelium, which consists of follicle-associated enterocytes and M cells that sample the surrounding microenvironment. M cells and other specialized cells beneath the epithelial barrier generate the antigen-specific response necessary for antibody production and generation of immunological memory. M cells have microfolds instead of microvilli and a basolateral pocket containing T and B lymphocytes, macrophages, and dendritic cells (92). Activated dendritic cells travel via the lymphatics to the gut-draining mesenteric lymph nodes, where they present antigens to naïve T cells and coordinate adaptive responses (64).

Interestingly in helminth infections, three specialized epithelial cell subtypes are prominent: the goblet cells, Paneth cells, and tuft cells. Goblet cells secrete mucus, trefoil peptides, and resistin-like molecules, which make up mucus (88). These are secreted by exocytosis in response to external stimuli, such as microbes, cytokines, and inflammation. The mucus functions as a lubricant and helps maintain the barrier between the epithelium and the intestinal microbiota (109). Paneth cells are present at the base of crypts in the small intestine and play a dual role in nourishing adjacent intestinal stem cells and releasing important antimicrobial molecules (25), including lysozyme, phospholipase A2, and antimicrobial defenses. Very recently, a little-studied epithelial cell type, the tuft cell, has been discovered to play a major role in antihelminth immunity, through the production of the alarmin IL-25 (56, 76, 177). Mice lacking the transcription factor required for tuft cell differentiation, Pou2f3, are devoid of Tuft cells and unable to expel intestinal helminths unless exogenous IL-25 is administered (56).

In intestinal helminth infection, alarmin release and production of Th2 cytokines stimulate muscle peristalsis and epithelial fluid egress, constituting a “weep and sweep” model for...
helminth expulsion. As well as goblet cell mucus release, mast cell proteases degrade tight junctions and allow intestinal fluids to leak into the intestinal lumen (110), and the smooth muscle contracts to effectively sweep the helminths away (4, 99, 103). In addition, epithelial cells increase their rate of turnover to produce an “epithelial escalator” to expel the helminth (26).

Inflammatory Bowel Diseases

Ulcerative colitis (UC) and Crohn’s disease (CD) are both IBDs that result in significant long-term morbidity and mortality (118). CD results in predominantly gastrointestinal symptoms, including abdominal pain, fever, and diarrhea with blood and mucus (14). The disease can manifest anywhere along the GI tract and can also result in nongastrointestinal features such as uveitis and enteropathic arthritis. UC affects the colonic mucosa and predominantly presents with bloody diarrhea (134), and also differs immunologically from CD in displaying an atypical Th2-like inflammatory condition (35).

Celiac disease is an autoimmune gluten-sensitive small-intestinal enteropathy triggered by gluten in cereals (123, 162). This can present with diarrhea, abdominal pain, distension, and vitamin deficiency, as well as failure to thrive in children. Celiac disease is treated by consuming a gluten-free diet; however, there are cases of refractory disease that may benefit from immunomodulatory therapies.

IBD is accompanied by a high level of T-cell cytokine production, in particular, expansion of inflammatory Th1 cells; under control of the transcription factor Tbet, Th1 cells produce IFN-γ and TNF in response to appropriate costimulatory signals from gut antigen-presenting dendritic cells (DCs) and macrophages. In experimental mouse models of IBD, the effect of regulatory T cells is decisive in determining disease progression. In mice lacking T and B cells, [for example, SCID or recombination-activating gene (RAG) deficient], the lymphocyte compartment can be reconstituted by the transfer of syngeneic cells from wild-type donors. However, if regulatory T cells are depleted from the transferred population, the remaining CD4+ effector T-cell populations cause a chronic colitis with a Th1 pattern of cytokine synthesis (IFN-γ and TNF) (106, 139).

IBD-like colitis can also be generated by stimulating innate cells in RAG-deficient mice with anti-CD40 activating antibodies (172) or by causing gross epithelial damage with agents, such as dextran sodium sulfate (DSS) (133). Blocking TNF reduces the severity of DSS colitis in mouse models (89), and, indeed, as discussed below, UC and CD have been successfully treated by blocking antibodies to TNF.

In addition to IFN-γ and TNF, the IL-23/IL-17 axis is prominent in IBD; for example, Th17 cytokines are elevated in human IBD (52). In a model of innate gut inflammation driven by Helicobacter hepaticus infection in RAG−/− mice, IL-23 instigates colitis and is produced by an innate lymphoid cell population, the ILC3 subset (19). In immunologically intact mice, Th17 cells also produce IL-22, a member of the IL-10 family of cytokines, which may protect against colitis. In mouse DSS-induced colitis, IL-22 delivery attenuated disease (166), while IL-22−/− mice suffered greater weight loss compared with wild-type mice. Likewise, in a T-cell transfer model of colitis, transfer of IL-22−/− T cells resulted in a more severe phenotype of colitis than in mice infused wild-type T cells (187). Innate lymphoid cell production of IL-22, stimulated through the prostaglandin pathway, is also required to maintain gut barrier integrity (39). While in human ulcerative colitis, IL-22+ T cells were linked to amelioration of symptoms (17), in Crohn’s disease, the expression of IL-22+ T cells within inflamed mucosa act to increase expression of inflammatory cytokines within subepithelial myofibroblasts, and so the role of IL-22 may be highly context dependent.

As type 2 immune cells (e.g., Th2 and M2 macrophages) drive contrasting responses to Th1 and Th17 cell phenotypes, they may be beneficial where the latter subsets mediate pathology. One route by which type 2 responses can counteract colitis is through the intestinal macrophage population, the largest of any tissue in the body (12). In mouse models of IBD, IL-4/IL-13 has been used to polarize macrophages to the M2 phenotype, and transferring these macrophages results in an ameliorated phenotype of colitis (31, 78). Tregs are also key mediators of protection against colitis, as their inclusion together with effector T cells results in protection against disease in the T-cell transfer model (122, 158).

The crucial role of Treg-associated cytokines is supported by the observation that TGF-β1−/− mice develop multiorgan lymphoproliferative disease of the gut (94, 96) while, IL-10−/− and IL-10R−/− mice develop a spontaneous colitis (93, 157). Again, macrophages are implicated in pathogenesis, as when lacking IL-10R, they are intrinsically proinflammatory and cause spontaneous colitis in mice, while pediatric patients with mutations in the IL-10 receptor have more proinflammatory macrophages and an IBD-like phenotype (157, 190).

Anticytokine therapy is a key current treatment of IBD, with the use of anti-TNF antibodies, such as infliximab and adalimumab. The antibody uestinumab, which acts against p40 (the common subunit of IL-23 and IL-12), may be useful in IBD because of its role in blocking the differentiation of naïve T cells to Th1 and Th17 cells; however, other anticytokine reagents show little effect or make disease worse (e.g., secukinumab: anti-IL-17A antibody), implying individual cytokines may have proinflammatory and anti-inflammatory effects (128). Vedolizumab is a monoclonal antibody against α4β7-integrin and results in gut-specific anti-inflammatory activity (46, 85). SMAD7, an intracellular protein that blocks TGF-β signaling, can be targeted in vivo. Mongersen, an oral SMAD7 antisense oligonucleotide, upregulates anti-inflammatory TGF-β effects and also shows promising results in therapy of Crohn’s disease (119).

Newer approaches to treatment of IBD include a trial of Treg therapy (36). Peripheral blood Tregs were isolated from patients and expanded in vitro in the presence of ovalbumin, before reinfusion into the same individual; this resulted in a reduction in the Crohn’s disease activity score but did not reach clinical significance (36). With growing interest in the immunomodulatory properties of helminth parasites, the use of helminths or their products has also attracted attention as a potential novel therapy, as outlined below.

Modulation of IBD by Helminths and Their Products

As discussed above, epidemiological studies have indicated that populations with higher helminth parasite burdens suffer fewer immune inflammatory conditions, such as allergy (114) and inflammatory bowel disease, and Crohn’s disease is known
to be less frequent in helminth-endemic countries (40). A substantial number of experimental animal models have also been used to show amelioration of colitic disease by helminth infections (Table 2), with studies encompassing all three of the helminth taxonomical groups: the cestodes, nematodes, and trematodes. Interestingly, reports from two different parasite models (with cestode and trematode infections) have implicated macrophage populations in helminth-generated protection against intestinal pathology (78, 160). Mechanistically, induction of IL-10 has been a recurrent theme in analyses of cytokine levels in helminth-infected mice (77) alongside a generalized switch from Th1 to Th2 cytokine production (169), while the helminth-induced expansion of Tregs that suppress colitis has also been demonstrated (66).

Colitis can be induced in a number of animal models, in each of which, authors have demonstrated the effectiveness of helminth infections, or exposure to helminth eggs, in reducing disease severity scores, improving histological inflammation, and in dampening inflammatory cytokine profiles, such as IFN-γ and IL-17 (Table 2). The impact of different species in each model reflects the ability of helminths to promote chronicity of infection and immunological tolerance through a variety of mechanisms (113, 161).

One widely studied helminth model is the murine intestinal nematode *Heligmosomoides polygyrus* (144). In early studies, it was shown that the propensity of IL-10-deficient mice to develop colitis (exacerbated by administration of the nonsteroidal anti-inflammatory drug piroxicam) was ameliorated by infection (42), and the same protective effect was shown that the propensity of IL-10-deficient mice to develop colitis (exacerbated by administration of the nonsteroidal anti-inflammatory drug piroxicam) was ameliorated by infection (42), and the same protective effect was ameliorated by infection (42), and the same protective effect was observed when transferring IL-10-deficient T cells to RAG-deficient mice, which normally develop severe colitis (115). In more direct and acute, models of colitis, it has been found that both BALB/c and C57BL/6 mice given infective *H. polygyrus* larvae orally showed reduced severity of trinitrobenzenesulfonic acid (TNBS) colitis (156, 169), and increased mucosal electrical resistance, indicating improved barrier function (156). In addition, the fourth-stage larvae of the same parasite improved disease score and histopathology in BALB/c mice suffering the effects of DSS-induced colitis (37).

The *H. polygyrus* model has also been very instructive at the mechanistic level. Foxp3+ Treg cells isolated from the mesenteric lymph node of *H. polygyrus*-infected mice were adoptively transferred into RAG-/- mice and conferred protection from piroxicam-induced colitis, whereas Foxp3+ Treg cells from uninfected animals did not (15, 66); these data correlate with the known potency of *H. polygyrus* to activate the host Treg cell compartment (159). In addition, adoptive transfer of dendritic cells from *H. polygyrus*-treated mice in a RAG-/- T-cell transfer model improved histological inflammation: these DCs were able to block ovalbumin (OVA)-induced cytokine secretion in vitro (15).

Other live helminth infections found to be protective include the rat cestode tapeworm *Hymenolepis diminuta*; mice infected with this parasite showed improved clinical scores and histopathology in a dinitrobenzene sulfonic acid (DNBS)-induced model of colitis (77, 78). Interesting mechanistic studies in this system have shown that protection required established infection, as STAT6-deficient mice both cleared the parasite and developed severe colitis (77); moreover, protection by infection was abolished by anti-IL-10 blocking antibodies (77). Protection was found to be mediated via the dominant population of alternatively activated macrophages (AAMs) generated by *H. diminuta* infection; macrophage deactivation with clodronate-loaded liposomes reduced the effects of *H. diminuta*, while adoptive transfer of in vitro-generated AAMs was protective (78). Furthermore, protective myeloid cells could be generated in vivo by injection of *H. diminuta* antigens, with the resultant CD11b+/Ly6C+Ly6G- population able to block DSS-induced colitis in recipient animals (143). A broader network of regulatory cells are, however, generated during this infection, such that splenic regulatory B cells can also confer protection against colitis (141), as well as dendritic cells pulsed with *H. diminuta* antigen were also successfully transferred to treat a DNBS colitis (108). Most recently, the

Table 2. Effects of helminth infection or exposure on intestinal inflammation

| Model                        | Detail                              | Suppression                                      | Reference |
|------------------------------|-------------------------------------|--------------------------------------------------|-----------|
| *Heligmosomoides polygyrus*  | C57BL/6 piroxicam-induced           | Histopathology, IFN-γ and IL-12                  | (42)      |
| RAG transfer model           | IL-10−/− T cells + piroxicam        | Histopathology                                   | (115)     |
| TNBS colitis                 | IL-10−/− d14 infection, d4 colitis  | Histopathology                                   | (156)     |
| TNBS colitis                 | BALB/c d10 infection, d4 colitis    | Histopathology, IFN-γ and TNF                    | (169)     |
| RAG transfer model           | IL-10−/− T cells + piroxicam        | Histopathology, IFN-γ and IL-17                  | (15, 65, 66) |
| OVA-specific colitis         | OVA-specific T cells and oral OVA   | Histopathology, IFN-γ, and IL-17                 | (95)      |
| DSS colitis                  | BALB/c mice, up to 18 days          | Weight loss and fecal blood                      | (37)      |
| *Hymenolepis diminuta*       | DNBS colitis infection 8 days before DNBS | Clinical score, histopathology and Myeloperoxidase, IL-10 dependent | (77)      |
| *Schistosoma japonicum* and *S. mansoni* (Trematoda) | DSS colitis Infection 8 wk before DSS | Weight loss, colon shortening, disease activity index | (160)     |
| TNBS colitis                 | Mice exposed to Sm eggs             | Histopathology, IFN-γ, and mortality             | (41)      |
| TNBS colitis                 | Mice exposed to Sm eggs (freeze-thawed) | Histopathology, IFN-γ, and bacterial translocation | (188)     |
| TNBS colitis                 | Rats infected with Sm 7 days before TNBS | Histopathology and myelo-peroxidase          | (120)     |
| *Trichinella spiralis*       | DNBS colitis Infection 21 days before DNBS | Histopathology, IL-12 and myeloperoxidase     | (84)      |
| TNBS colitis                 | Infection 21 days after TNBS        | Histopathology, myeloperoxidase and mortality    | (189)     |

RAG, recombination activating gene; TNBS, trinitrobenzenesulfonic acid; OVA, ovalbumin; DSS, dextran sodium sulfate; DNBS, dinitrobenzene sulfonic acid.
protective effects of *H. diminuta* infection, and of the myeloid population induced by the parasite, have been shown to be inhibited by IL-22, but promoted by IL-25, with disease scores in DNBS-induced colitis exacerbated by anti-IL-25 antibody treatment (142).

In a similar manner, *Schistosoma mansoni* infections have also been shown to reduce the severity of experimental colitis in both DSS (160) and TNBS (120) models, again with involvement of the macrophage compartment (160). A number of investigators have also tested the ability of schistosome eggs, known to be potent immunomodulators, to influence colitis; eggs of both *S. mansoni* and a related species *S. japonicum* show protective effects, and Treg cells were found to be increased in spleens of *S. japonicum*-egg treated TNBS mice compared with TNBS alone (117). The exposure to *S. japonicum* eggs also resulted in reduced idiopathic bacterial transfer during TNBS colitis (188).

Finally, in another nematode infection system, *Trichinella spiralis* was also found to ameliorate both DSS- and TNBS-induced colitis (84, 189) but not the type 2-mediated oxazolone colitis (189). Although few mechanistic insights into this system are as yet available, there is a clear indication of a cytokine switch, resulting from infection, with reduced IL-12 and higher levels of type 2 cytokines in infected mice challenged with the colitis model (84, 189).

**Human Therapy**

Deliberate infection of humans with live parasites has already been tested for the potential to modulate these gut inflammatory diseases. In UC, a notable report was that from a single individual who self-medicated with *Trichuris trichiura*, the human whipworm (17). The patient’s symptoms resolved, and this was associated with increased IL-22 from T-helper cells, consistent with a protective effect for this cytokine, as discussed above. Experimental trials have also been performed with the hookworm *Necator americanus* in celiac disease patients (32, 33), whose clinical outcome demonstrated suppression of inflammatory cytokines (112). Infection also allowed patients with celiac disease to tolerate increasing gluten load and increased gut microbial richness (58).

The most widely used agent, however, has been the pig whipworm *Trichuris suis*, which was selected because it is short-lived in humans and minimally pathogenic (180). Administration of *T. suis* ova has been used successfully in small-scale trials to alleviate active CD and UC (44, 167, 168); however, two larger-scale trials, one including over 200 patients, were recently discontinued due to unusually high placebo response rates (44), and hence, the future of this approach has yet to be determined. A recent Cochrane review concluded that there is insufficient evidence to determine the safety and efficacy of helminth therapy for human IBD (53). Further randomized controlled trials are required to assess the efficacy of helminth infections as a treatment of inflammatory bowel disease.

A recent study on idiopathic chronic diarrhea in captive macaques also found alleviation of disease by deliberate helminth infection (18). Interestingly, this implied an increase in diversity of microbiota in association with *T. trichiura* infection. Potentially, the helminth infection restored intestinal diversity, an important cofactor to consider for future studies.

Currently, the landscape for live helminth therapy is uncertain; treatments have generally proven to be safe, but promising case reports and small-scale trials have not progressed successfully through large trials for a variety of logistical reasons, leaving us still short of an unequivocal randomized controlled study that would establish efficacy (44, 45).

**Molecular Approaches**

Although there is strong evidence that live parasite infections exert profound down-modulatory effects on the immune system of their hosts, the therapeutic application of deliberate parasite infection is fraught with ethical and practical problems (45, 81). Hence, the use of defined molecular products from the same parasites is being explored as potential immunomodulators. A number of groups are testing parasite products in immunological disorders of the gastrointestinal tract (Table 3).

**Table 3. Helminth products and proteins in intestinal inflammation**

| Molecules Detail | Suppression | Reference |
|------------------|-------------|-----------|
| **Nematode extracts and ES** | | |
| *Ancylostoma, canium* ES soluble proteins | DSS colitis | Histopathology, cytokines, weight loss | (47) |
| *Ancylostoma ceylanicum* ES extract | DSS colitis in BALB/c mice | Histopathology, cytokines, MPO | (20) |
| *Trichinella spiralis* larval extract | DNBS colitis in C57BL/6 mice | Histopathology, MPO, IL-1β response; raised TGF-β, IL-13 | (121) |
| *T. spiralis* ES | DSS colitis in C57BL/6 mice | Histopathology, disease activity, cytokines | (184) |
| **Nematode proteins** | | |
| *Anakis simplex* MIF homolog | DSS colitis in C57BL/6 mice | Disease activity index, weight loss | (23) |
| *Brugia malayi* asparaginyl-tRNA synthase | T-cell transfer model | Histopathology | (91) |
| *B. malayi* cystatin | DSS colitis in BALB/c mice | Disease activity score, histopathology | (85) |
| *B. malayi* ALT 2 protein | DSS colitis | Disease activity score, myeloperoxidase activity | (86) |
| *Toxocara leonina* galectin | DSS colitis in C57BL/6 mice | Disease activity index, weight loss; raised TGF-β, IL-10 | (87) |
| **Trematode extracts** | | |
| *Schistosoma mansoni* soluble proteins | TNBS colitis in Swiss mice | Histopathology, MPO, IFN-γ response | (150) |
| *S. mansoni* soluble extract | T-cell transfer model | Clinical disease score, colonoscopy, myeloperoxidase | (70) |
| **Trematode proteins** | | |
| *Clonorchis sinensis* cystatin | DSS colitis in C57BL/6 mice | Disease activity index | (80) |
| *S. mansoni* 28-kDa glutathione S-transferase (P28GST) | TNBS colitis in rats | Reduced clinical and histological scores, 50% reduction in colonic MPO | (38) |
| *Schistosoma japonicum* cystatin | TNBS colitis in BALB/c mice | Histology, cytokine responses | (179) |

ES, excitatory/secretory; MIF, migration inhibitory factor.
In earlier studies, parasite extracts or collections of excretory/secretory (ES) products were first tested for their protective effects against disease activity in a variety of mouse IBD models. Soluble extracts of the dog hookworm *Ancylostoma caninum* reduced clinical disease scores and abated the profile of inflammatory cytokines (IFN-γ, IL-17, and TNF) in both DSS- and TNBS-induced colitis models (20, 150). Likewise, both somatic extract and ES products from the closely related *A. ceylanicum* also suppressed DSS-induced colitis in mice (20), as did extract and ES from the pork nematode *Trichinella spiralis* (121, 184). Within the trematode models, soluble extracts of *S. mansoni* have protected mice against both TNBS-induced colitis (150), and in the T-cell transfer model into RAG-deficient hosts (70).

More recently, it has become possible to test individual defined products from helminth parasites, expressed as recombinant proteins; in principle, this approach should accelerate the translation from helminth infection to a molecular therapy for colitis. To date, however, only limited information has appeared, often lacking appropriate control proteins (such as inactive mutants, or even unrelated proteins expressed in the same recombinant vector). Nevertheless, it has been reported that *Brugia malayi* cytoplasmic asparaginyl-tRNA synthetase (BMAsnRS) improved colitis scores in a T-cell transfer model, an improvement attributed by the authors to the ability of BMAsnRS to bind IL-8 (91). Other *B. malayi* proteins linked to protection from colitis include ALT-2 (86), an abundantly expressed larval product previously shown to inhibit IFN-γ signaling (60) and CPI-2 or cystatin (85), which blocks antigen processing in mammalian cells (107). However, control inactive mutants of these proteins were not tested in the published reports.

Some studies have further explored the cellular mechanisms through which helminth products may protect from colitis. Similar to the parasites themselves, parasite-derived molecules predominantly stimulate a type 2 response in innate cells, as well as activate Tregs (Table 3). Innate immunity, in particular, plays an important role in ameliorating colitis severity, linked to IL-10 production. Interestingly, the macrophage migration inhibitory factor (MIF) homolog from *Anisakis simplex* (AsMIF) has also been shown to induce upregulation of IL-10 in both lymph node and intestinal epithelial cells, and also increases Foxp3+ Treg expression in mice subject to DSS-induced colitis (23). Returning to the cystatin family of inhibitors, a recombinant cystatin from *S. japonicum* (rSjCystatin)-induced Foxp3+ Treg cells and improved disease activity scores in TNBS-induced colitis (179), while a more distant homolog (CsStefin-1) from the liver fluke *Clonorchis sinensis* was shown to increase IL-10-positive macrophages in the DSS-induced colitis model (80).

In a similar vein, the galecint from the feline intestinal nematode *Toxascaris leonina*, provided modest protection against disease activity in DSS-induced colitis, while raising IL-10 and TGF-β responses (87), while a schistosome enzymatic protein, the 28-kDa glutathione-S-transferase, P28GST conferred a protective effect that was dependent on eosinophil infiltration, as the effect was absent in IL5−/− mice (38). Notably, each of the studies quoted here tested a single recombinant protein in the absence of controls that would exclude trivial immune deviation effects (from administration of an exogenous antigen) or potential contaminants introduced through the recombinant expression system.

**Conclusions and Outlook**

Inflammatory bowel diseases have been treated with powerful immunosuppressive medications such as Infliximab, which severely dampens the body’s ability to mount a protective response in an infection. Helminths have existed symbiotically with humans for many millennia and have developed sophisticated means of manipulating the immune system to their advantage without greatly compromising antimicrobial defenses. The discovery that helminths and helminth-derived products can alleviate colitic disease in model systems may, thus, be key in deriving novel compounds that are effective against a range of autoimmune diseases, while maintaining the ability to fight bacterial infections.

**GRANTS**

F. Varyani and R. M. Maizels gratefully acknowledge funding support from The Wellcome Trust, through the Edinburgh Clinical Academic Track (ECAT) and a Senior Investigator Award (Ref. 106122), respectively. J. O. Fleming gratefully acknowledges funding support from the National Multiple Sclerosis Society, USA (RG 3613A4/I). R. M. Maizels is also funded through the Wellcome Centre for Molecular Parasitology, supported by core funding from the Wellcome Trust (Ref. 104111).

**DISCLOSURES**

No conflicts of interest, financial or otherwise, are declared by the authors.

**AUTHOR CONTRIBUTIONS**

F.V., J.O.F., and R.M.M. drafted manuscript; F.V., J.O.F., and R.M.M. edited and revised manuscript; F.V., J.O.F., and R.M.M. approved final version of manuscript.

**REFERENCES**

1. Allen JE, Maizels RM. Diversity and dialogue in immunity to helminths. *Nat Rev Immunol* 11: 375–388, 2011. doi: 10.1038/nri2992.
2. Allen JE, Sutherland TE. Host protective roles of type 2 immunity: parasite killing and tissue repair: flip sides of the same coin. *Semin Immunol* 26: 329–340, 2014. doi: 10.1016/j.smim.2014.06.003.
3. An D, Oh SF, Olszak T, Neves JF, Avcı FY, Erturk-Hadsemir D, Lu X, Zeissig S, Blumberg RS, Kasper DL. Sphingolipids from a symbiotic microbe regulate homeostasis of host intestinal natural killer T cells. *Cell* 156: 123–133, 2014. doi: 10.1016/j.cell.2013.11.042.
4. Anthony RM, Rutitzky LJ, Urban JF Jr, Stadecker MJ, Gause WC. Protective immune mechanisms in helminth infection. *Nat Rev Immunol* 7: 975–987, 2007. doi: 10.1038/nri2199.
5. Araujo MI, Lopes AA, Medeiros M, Cruz AA, Sousa-Atta L, Solé D, Carvalho EM. Inverse association between skin response to aerollergens and *Schistosoma mansoni* infection. *Int Arch Allergy Immunol* 123: 145–148, 2000. doi: 10.1159/000024434.
6. Artis D. Epithelial-cell recognition of commensal bacteria and maintenance of immune homeostasis in the gut. *Nat Rev Immunol* 8: 411–420, 2008. doi: 10.1038/nri2316.
7. Aslani S, Mahmoudi M, Karami J, Jamshidi AR, Malekshahi Z, Nicknam MH. Epigenetic alterations underlying autoimmune diseases. *Autoimmunity* 49: 69–83, 2016. doi: 10.3109/08916934.2015.1134511.
8. Atarashi K, Tanoue T, Shima T, Imaoka A, Katsuta K, Momose Y, Chen G, Yamakuni T, Saito T, Obha Y, Taniguchi T, Takeda K, Hori S, Ivanov II, Umesaki Y, Itos K, Honda K. Induction of colonic regulatory T cells by indigenous *Clostridia* strains. *Science* 331: 337–341, 2011. doi: 10.1126/science.1198409.
9. Atarashi K, Tanoue T, Oshima K, Suda W, Nagano Y, Nishikawa H, Fukuda S, Saito T, Narushima S, Hase K, Kim S, Fritz JV, Wilmes P, Ueha S, Matsushima K, Ohno H, Ohs H, Sakaguchi S, Taniguchi T, Morita H, Hattori M, Honda K. Treg induction by a rationally selected mixture of *Clostridia* strains from the human microbiota. *Nature* 500: 232–236, 2013. doi: 10.1038/nature12331.
46. Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, Van Asche G, Axler J, Kim JJ, Danese S, Fox I, Milch C, Sankoh S, Wyant T, Xu J, Parikh A; for the GEMINI 1 Study Group. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 369: 699–710, 2013. doi:10.1056/NEJMoa1215734.

47. Grainger JR, Smith KA, Hewitson JP, McSorley HJ, Harcus Y, Blackburn CC, Maizels RM. Helminth secretions induce activation of microbial-associated Toll-like receptors and have a role in the pathogenesis of inflammatory bowel disease. PLoS Negl Trop Dis 6: e1000250, 2012. doi:10.1371/journal.pntd.0002501.

48. Garg SK, Croft AM, Bager P. Autoimmune disease and parasitic infections in Nigeria. J Immunol 189: 1395–1405, 2012. doi:10.4049/jimmunol.1201457.

49. Guse W, Wyna TT, Allen JE. Type 2 immunity and wound healing: evolutionary refinement of adaptive immunity by helminths. Nat Rev Immunol 13: 607–614, 2013. doi:10.1038/nri3476.

50. Han J, Setiawan T, Blum AM, Urban JP Jr, Stoyanoff KM, Weinstock VP, Carson SS, McMahon PM, Lu H, Lavoie S, Blum AM, Tran SV, Weinstock JV. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 62: 226–230, 2014. doi:10.1136/gut.2012.303198.

51. Han J, Blum AM, Setiawan T, Urban JP Jr, Stoyanoff KM, Weinstock JV. Heligmosomoides polygyrus bakeri infection activates colonic Foxp3+ T cells enhancing their capacity to prevent colitis. J Immunol 191: 1927–1934, 2013. doi:10.4049/jimmunol.1201457.

52. Hanski I, von Hertzen L, Fryhquist N, Koskinen K, Torppa K, Laatikainen T, Karisola P, Auvrin P, Paulin L, Mäkelä MJ, Vartiaienen E, Kosunen TU, Alenius H, Haathtela T. Environmental biodiversity, human microbiota, and allergy are interrelated. Proc Natl Acad Sci USA 109: 8334–8339, 2012. doi:10.1073/pnas.1205624109.

53. Helmy H. Human helminth therapy to treat inflammatory disorders: where do we stand? BMC Immunol 16: 12, 2015. doi:10.1186/s12870-015-0074-3.

54. Hernandez JL, Leung G, McKay DM. Cestode regulation of inflammation and inflammatory diseases. Int J Parasitol 43: 233–243, 2013. doi:10.1016/j.ijpara.2012.09.005.

55. Heylen M, Ryussens NE, De Man JG, Timmermans JP, Pelckmans PA, Moorels TG, De Winter BY. Worm proteins of Schistosoma mansoni reduce the severity of experimental chronic colitis in mice by suppressing colonic proinflammatory immune responses. PLoS One 9: e10002, 2014. doi:10.1371/journal.pone.0110002.

56. Heylen M, Ryussens NE, Giels EM, Vanhommegem E, Pelckmans PA, Moorels TG, De Man JG, De Winter BY. Of worms, mice and man: an overview of experimental and clinical helminth-based therapy for inflammatory bowel disease. Pharmacol Ther 143: 153–167, 2014. doi:10.1016/j.pharma.2014.02.011.

57. Hoekstra MA, Lazaro C, Postma JD, de Winther MP, Dijkstra CD, van Die I, Kooij G. Treatment with Trichuris suis soluble products during monocyte-to-macrophage differentiation reduces inflammatory responses through epigenetic remodeling. FASEB J 30: 2826–2836, 2016. doi:10.1096/fasebj.201003438.

58. Hooper LV, Littman DR, Macpherson AJ. Interactions between the microbiota and the immune system. Science 336: 1268–1273, 2012. doi:10.1126/science.1226889.

59. Hoheisel MJ, Molynieux DH, Fenwick A, Kumaresan J, Sachs JD, Savioli L. Control of neglected tropical diseases. N Engl J Med 357: 1018–1027, 2007. doi:10.1056/NEJMra0604142.

60. Hoj J, Czarnota K, Cvikl O, Hermann T, Brzozowska T, Varga K, Balazs M, Tsangaris T, Kappeler E, Bethony JM, King CH, Pearce EJ, Hoekstra MA, Lazaro C, Postma JD, de Winther MP, Dijkstra CD, van Die I, Kooij G, Hart AA, Nunez DI. Treatment with Trichuris suis soluble products during monocyte-to-macrophage differentiation reduces inflammatory responses through epigenetic remodeling. FASEB J 30: 2826–2836, 2016. doi:10.1096/fasebj.201003438.

61. Hooper LV, Littman DR, Macpherson AJ. Interactions between the microbiota and the immune system. Science 336: 1268–1273, 2012. doi:10.1126/science.1226889.

62. Howitt MR, Lavoie S, Michaud M, Blum AM, Tran SV, Weinstock JV, Gallini CA, Redding K, Margolskee RF, Osborne LC, Artis D, Garrett WS. Tuft cells, taste-chemosensory cells, orchestrate parasite type 2 immunity in the gut. Science 351: 1329–1333, 2016. doi:10.1126/science.aaf1648.

63. Hunter MM, Wang A, Hirota CL, McKay DM. Neutralizing anti-IL-10 antibody blocks the protective effect of tapeworm infection in a murine model of chemically induced colitis. J Immunol 174: 7368–7375, 2005. doi:10.4049/jimmunol.174.11.7368.

64. Hunter MM, Wang A, Hu WS, Johnson MJG, Van Rooijen N, Beck PL, McKay DM. In vitro-derived alternatively activated macrophages reduce colonic inflammation in mice. Gastroenterology 138: 1395–1405, 2010. doi:10.1053/j.gastro.2009.12.041.

65. Izcue A, Coombes JL, Powrie F. Regulatory lymphocytes and intestinal inflammation. Annu Rev Immunol 27: 313–338, 2009. doi:10.1146/annurev.immunol.021908.132657.

66. Jang SW, Cho MK, Park MK, Kang SA, Na B-K, Ahn SC, Kim DH, Yu HS. Parasitic helminth cystatin inhibits DSS-induced intestinal inflammation via IL-10”/NfκB(0)” macrophage recruitment. Korean J Parasitol 49: 245–251, 2011. doi:10.3347/kjp.2011.49.3.245.

67. Johnston CJ, Smyth DJ, Dresser DW, Maizels RM. TGF-β in tolerance, development and regulation of immunity. Cell Immunol 299: 14–22, 2016. doi:10.1016/j.cellimm.2015.10.006.

68. Jung C, Hugot JP, Barreau F. Peyers’ patches: the immune sensors of the intestine. Int J Inflamm 10: 823710, 2010. doi:10.4061/2010/823710.

69. Karimi K, Inman MD, Bienenstock J, Forsythe P. Lactobacillus reuteri-induced regulatory T cells protect against an allergic airway response in mice. Am J Respir Crit Care Med 179: 186–193, 2009. doi:10.1164/rccm.200806-951OC.

70. Khan WI, Blennerhasset PA, Varghese AK, Chowdhury SK, Omsted P, Deng Y, Collins SM. Intestinal nematode infection ameliorates experimental colitis in mice. Infect Immun 70: 5931–5937, 2002. doi:10.1128/IAI.70.9.5931-5937.2002.

71. Khatri V, Amadare N, Tanevkar A, Goswami K, Reddy MV. Brugia malayi cystatin therapeutically ameliorates dextran sulfate sodium-induced..
86. Maizels RM, Amdare N, Yadav RS, Tarnkar A, Goswami K, Reddy MV. Brugia malayi abundant larval transcript 2 protein treatment attenuates experimentally induced colitis in mice. *Indian J Exp Biol* 53: 732–739, 2015.

87. Kim JY, Cho MK, Choi SH, Lee KH, Ahn SC, Kim DH, Yu HS. Inhibition of dextran sulfate sodium (DSS)-induced intestinal inflammation via enhanced IL-10 and TGF-β production by gallocatein-9 homologues isolated from intestinal parasites. *Mol Biochem Parasitol* 174: 53–61, 2010. doi:10.1016/j.molbiopara.2010.06.014.

88. Kim YS, Ho SB. Intestinal goblet cells and mucus in health and disease: recent insights and progress. *Curr Gastroenterol Rep* 12: 319–330, 2010. doi:10.1007/s11894-010-0131-2.

89. Kojouharoff G, Hans W, Obermeier F, Männel DN, Andus T, Schölmerich J, Gross V, Falk W. Neutralization of tumour necrosis factor (TNF) but not of IL-1 reduces inflammation in chronic dextran sulphate sodium-induced colitis in mice. *Clin Exp Immunol* 107: 353–358, 1997. doi:10.1111/j.1451-722X.1997.tb1184.x.

90. Kreider T, Anthony RM, Urban JR Jr, Gause WC. Alternatively activated macrophages in helminth infections. *Curr Opin Immunol* 19: 455–467, 2007. doi:10.1016/j.coi.2007.07.002.

91. Kron MA, Metwali A, Vodanovic-Jankovic S, Elliott D. Nematode asparaginyl-RNA synthetase resolves intestinal inflammation in mice with T-cell transfer colitis. *Clin Vaccine Immunol* 20: 276–281, 2013. doi:10.1128/CVI.00594-12.

92. Kucharczyk T, Lügering N, Rautenberg K, Löhler J, Rennick D, Rajewsky K, Müller W. Inhibition of dextran sulfate sodium (DSS)-induced intestinal inflammation in mice by helminths. *Mol Biochem Parasitol* 53–61, 2010. doi:10.1016/j.molbiopara.2010.06.014.

93. Kühn R, Löhler J, Rennick D, Rajewsky K, Müller W. Interleukin-10-deficient mice develop chronic enterocolitis. *Cell* 75: 263–274, 1993. doi:10.1016/0092-8674(93)80068-P.

94. Kulkarni AB, Huh C-G, Becker A, Geiser A, Lyght M, Flanders KC, Roberts AB, Sporn MB, Ward JM, Karlsson S. Transforming growth factor β1 null mutation in mice causes excessive inflammatory response and early death. *Proc Natl Acad Sci USA* 90: 770–774, 1993. doi:10.1073/pnas.90.2.770.

95. Leung J, Hang L, Blum A, Setiawan T, Stoll R, Domchek W. Role of M cells in intestinal barrier function. *Ann N Y Acad Sci* 915: 171–183, 2000. doi:10.1111/j.1469-6632.2000.tb08526.x.

96. Kühn R, Löhler J, Rennick D, Rajewsky K, Müller W. Interleukin-10-deficient mice develop chronic enterocolitis. *Cell* 75: 263–274, 1993. doi:10.1016/0092-8674(93)80068-P.

97. Loukas A. Helminth infections and the control of human allergic and autoimmune disorders. *Clin Microbiol Infect* 22: 481–486, 2016. doi:10.1016/j.cmi.2016.04.024.
eczema: randomized-controlled trial results. Pediatr Allergy Immunol 22: 305–312, 2011. doi:10.1111/j.1399-3038.2010.01122.x.

125. Mutapi F, Imai N, Nausch N, Bourke CD, Rujeni N, Mitchell KM, Midzi N, Woolhouse ME, Maizels RM, Mdluluza T. Schistosome infection intensity is inversely related to auto-reactive antibody levels. PLoS One 6: e19149, 2011. doi:10.1371/journal.pone.0019149.

126. Navarro S, Ferreira I, Loukas A. The hookworm pharmacopoeia for inflammatory diseases. Int J Parasitol 43: 225–231, 2013. doi:10.1016/j.ijpara.2012.11.005.

127. Neill DH, Wong SH, Bellosi A, Flynn RJ, Daly M, Langford TKA, Bucks C, Kane CM, Fallon PG, Pannell R, Jolin HE, McKenzie AN. Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature 464: 1367–1370, 2010. doi:10.1038/nature08900.

128. Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol 14: 329–342, 2014. doi:10.1038/nri3661.

129. Noverr MC, Huffnagle GB. The ‘microflora hypothesis’ of allergic diseases. Clin Exp Allergy 35: 1511–1520, 2005. doi:10.1111/j.1365-2222.2005.02379.x.

130. Nutman TB. Looking beyond the induction of Th2 responses to explain immunomodulation by helminthes. Parasit Immunol 37: 304–313, 2015. doi:10.1111/pim.12194.

131. O’Hollohan DR, Zaman V. Treatment of Brugia malayi infection with levamisole. J Trop Med Hyg 77: 113–115, 1974.

132. Obata Y, Furusawa Y, Hase K. Epigenetic modifications of the immune system in health and disease. Immunol Cell Biol 93: 226–232, 2015. doi:10.1038/mi.2014.114.

133. Okayasu I, Hatakeyama S, Yamada M, Obkusa T, Inagaki Y, Nakaya R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 98: 694–702, 1990. doi:10.1016/S0016-5085(90)90290-H.

134. Ordás I, Eckmann L, Talaminí M, Baumgart DC, Sandborn WJ. Ulcerative colitis. Lancet 380: 1606–1619, 2012. doi:10.1016/S0140-6736(12)60150-0.

135. Pearce EJ, MacDonald AS. The immunobiology of schistosomiasis. Nat Rev Immunol 2: 499–511, 2002. doi:10.1038/nri729.

136. Peterson LW, Artis D. Intestinal epithelial cells: regulators of barrier function and immune homeostasis. Nat Rev Immunol 14: 141–153, 2014. doi:10.1038/nri3608.

137. Pineda MA, Eason RJ, Harnett MM, Harnett W. Helminthes in the gastrointestinal tract. Microbial ‘old friends’, immunoregulation and socioeconomic status. Clin Exp Immunol 177: 1–12, 2014. doi:10.1111/cei.12269.

138. Rook GA, Raison CL, Lowry CA. Microbial ‘old friends’, immunoregulation and socioeconomic status. Clin Exp Immunol 177: 1–12, 2014. doi:10.1111/cei.12269.

139. Rooks MG, Garrett WS. Gut microbiota, metabolites and host immunity. Nat Rev Immunol 16: 341–352, 2016. doi:10.1038/nri.2016.42.

140. Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol 9: 313–323, 2009. doi:10.1038/nri2515.

141. Round JL, Mazmanian SK. Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota. Proc Nat Acad Sci USA 107: 12204–12209, 2010. doi:10.1073/pnas.0909212107.

142. Ruysers NE, De Winter BY, De Man JG, Loukas A, Pearson MS, Weinstock JV, Van den Bosche RM, Martinet W, Pellekans PA, Moreels TG. Therapeutic potential of helminth-soluble proteins in TNBS-induced colitis in mice. Inflamm Bowel Dis 15: 491–500, 2009. doi:10.1097/IBD.0b013e3181b20787.

143. Saeed S, Quintin J, Kerstens HH, Rao NA, Aghajani-Farahi A, Matarese F, Cheng SC, Ratter J, Berentsen K, van der Ent MA, Sharifi N, Janssen-Megens EM, Ter Huurne M, Mandoli A, van Schaijk T, Ng A, Burden F, Downes K, Frontini M, Kumar V, Giamarellos-Bourboulis EJ, Ouwehand WH, van der Meer JW, Joosten LA, Wijmenga C, Martens JH, Xavier RJ, Logie C, Netea MG, Stunnenberg HG. Epigenetic programming of monocyte-to-macrophage differentiation and trained innate immunity. Science 345: 1251086, 2014. doi:10.1126/science.1251086.

144. Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 22: 531–562, 2004. doi:10.1146/annurev.immunol.21.120601.141122.

145. Santiago HC, Nutman TB. Human helminths and allergic disease: the hygiene hypothesis and beyond. Am J Trop Med Hyg 95: 746–753, 2016. doi:10.4269/ajtmh.16-0348.

146. Sawant DV, Gravano VG, Vogel P, Giacomini P, Arts D, Vignali DAA. Regulatory T cells limit induction of protective immunity and promote immune pathology following intestinal helminth infection. J Immunol 192: 2904–2912, 2014. doi:10.4049/jimmunol.1202502.

147. Selmi C, Lu Q,Humble MC. Heritability versus the role of the environment in autoimmune disease. Autoimmun Rev 39: 249–252, 2012. doi:10.1016/j.autrev.2012.07.011.

148. Setiawan T, Metwali A, Blum AM, Ince MN, Urban JF Jr, Elliott DE, Weinstock JV. Heligmosomoides polygyrus promotes regulatory T-cell cytokine production in the murine normal distal intestine. Infect Immun 75: 4655–4663, 2007. doi:10.1128/IAI.00358-07.

149. Shouval DS, Biswas A, Goettel JA, McCann K, Conway E, Redhu NS, Mascanfronic ID, Al Adham Z, Lavoie S, Bourk M, Nguyen DD, Samsom JN, Escher JC, Somech R, Weiss B, Beier R, Conklin LS, Ebens CI, Santos FG, Ferreira AR, Sherlock M, Bhan AK, Müller W, Mora JR, Quintana FJ, Klein C, Muise AM, Horwitz BH, Snapper SB. Interleukin-10 signaling in innate immune cells regulates mucosal immune tolerance and anti-inflammatory macrophage function. Immunity 40: 706–719, 2014. doi:10.1016/j.immuni.2014.03.011.

150. Singh B, Read S, Asseman C, Malmström V, Mottet C, Stephens LA, Travnikova R, Tlaskalova H, Powrie F. Control of intestinal inflammation by regulatory T cells. Immunol Rev 182: 190–200, 2001. doi:10.1111/j.1600-065X.2001.1820115.x.

151. Smith KA, Filby KJ, Reynolds IA, Hewitson JP, Harcus Y, Boon L, Sparwasser T, Hämmerling G, Maizels RM. Low-level regulatory T-cell activity is essential for functional type-2 effector immunity to expel gastrointestinal helminths. Mucosal Immunol 9: 428–443, 2016. doi:10.1038/mi.2015.73.

152. Smith P, Mangan NE, Walsh CM, Fallon RE, McKenzie AN, van Rooijen N, Fallon PG. Infection with a helminth parasite prevents experimental colitis via a macrophage-mediated mechanism. J Immunol 178: 4557–4566, 2007. doi:10.4049/jimmunol.178.7.4557.

153. Smits HH, Everts B, Hartgers FC, Yazdanabaksh M. Chronic helminth infections protect against allergic diseases by active regulatory processes. Curr Allergy Asthma Rep 10: 3–12, 2010. doi:10.1007/s11882-009-0085-3.

154. Stamnaes J, Sollid LM. Celiac disease: Autoimmunity in response to food antigen. Semin Immunol 27: 343–352, 2015. doi:10.1016/j.smim.2015.11.001.

155. Steel C, McCarthy JS, Ottesen EA, Guinea A. Long-term effect of prenatal exposure to maternal microfloraemia on immune responsiveness
to filarial parasite antigens. *Lancet* 343: 890–893, 1994. doi:10.1016/S0140-6736(94)90009-9.

164. Sackinger E, Timmermann N, Blumberg RS, Wilcox WR, Stüber H, von Mutius E, et al. Helminth infections decrease host susceptibility to immune-mediated diseases. *J Immunol* 193: 3239–3247, 2014. doi:10.4049/jimmunol.1400927.

165. Urban JF Jr, Noben-Trauth N, Donaldson DD, Madden KB, Morris SC, Collins M, Finkelman FD. IL-13, IL-4R, and Stat6 are required for the expulsion of the gastrointestinal nematode parasite *Nippostrongylus brasiliensis*. *Immunity* 8: 255–264, 1998. doi:10.1016/S1074-7613(00)00206-3.

166. Voehringer D, Shinkai K, Locksley RM. Type 2 immunity reflects orchestrated recruitment of cells committed to IL-4 production. *Immunity* 20: 267–277, 2004. doi:10.1016/S1074-7613(04)00026-3.

167. von Moltke J, Ji M, Liang HE, Locksley RM. T-cell-derived IL-25 regulates an intestinal ILC2-epithelial response circuit. *Nature* 529: 221–225, 2016. doi:10.1038/nature16161.

168. von Mutius E. 99th Dahlem Conference on Infection, Inflammation and Chronic Inflammatory Disorders: farm lifestyles and the hygiene hypothesis. *Clin Exp Immunol* 160: 130–135, 2010. doi:10.1111/j.1662-2299.2010.04138.x.

169. Wang S, Xie Y, Yang X, Wang X, Yan K, Zhong Z, Wang X, Xu Y, Zhang Y, Liu F, Shen X. Therapeutic potential of recombinant cystatin from *Schistosoma japonicum* in TNBS-induced experimental colitis of mice. *Parasit Vectors* 9: 6, 2016. doi:10.1186/s13071-015-1288-1.

170. Weinstock JV. Autoimmunity: The worm returns. *Nature* 491: 183–185, 2012. doi:10.1038/491183a.

171. Weinstock JV, Elliott DE. Helminth infections decrease host susceptibility to immune-mediated diseases. *J Immunol* 193: 3239–3247, 2014. doi:10.4049/jimmunol.1400927.

172. Weng NP, Araki Y, Subedi K. The molecular basis of the memory T-cell response: differential gene expression and its epigenetic regulation. *Nat Rev Immunol* 12: 306–315, 2012. doi:10.1038/nri3173.

173. Wilson MS, Taylor MD, Balic A, Finney CAM, Lamb JR, Maizels RM. Suppression of allergic airway inflammation by helminth-induced regulatory T cells. *J Exp Med* 202: 1199–1212, 2005. doi:10.1084/jem.20042572.

174. Yang X, Yang Y, Wang Y, Zhan B, Gu Y, Cheng Y, Zhu X. Excretory/secretory products from *Trichinella spiralis* adult worms ameliorate DSS-induced colitis in mice. *PLoS One* 9: e96545, 2014. doi:10.1371/journal.pone.0096654.

175. Yazdanbakhsh M, Kremsner PG, van Ree R. Allergy, parasites, and the hygiene hypothesis. *Science* 296: 490–494, 2002. doi:10.1126/science.296.5567.490.

176. Zacccone P, Burton O, Miller N, Jones FM, Dunne DW, Cooke A. *Schistosoma mansoni* egg antigens induce Treg that participate in diabetes prevention in NOD mice. *Eur J Immunol* 39: 1098–1107, 2009. doi:10.1002/eji.200838871.

177. Zhao Y, Zhang S, Jiang L, Jiang J, Liu H. Preventive effects of *Schistosoma japonicum* ova on trinitrobenzenesulfonic acid-induced colitis and bacterial translocation in mice. *J Gastroenterol Hepatol* 24: 1775–1780, 2009. doi:10.1111/j.1440-1746.2009.05986.x.

178. Zhao Y, Liu MY, Wang XL, Liu XL, Yang Y, Zou HB, Sun SM, Yu L, Rosenthal B, Shi HN, Boireau P, Wu XP. Modulation of inflammatory bowel disease in a mouse model following infection with *Trichinella spiralis*. *Vet Parasitol* 194: 211–216, 2013. doi:10.1016/j.vetpar.2013.01.058.

179. Zigmond E, Bernshtein B, Friedlander G, Walker CR, Yona S, Kim KW, Brenner O, Krauthgamer R, Varol C, Müller W, Jung S. Macrophage-restricted interleukin-10 receptor deficiency, but not IL-10 deficiency, causes severe spontaneous colitis. *Immunity* 40: 720–733, 2014. doi:10.1016/j.immuni.2014.03.012.